News
First treatment option indicated for CKD in Scotland for 20 years
AstraZeneca today announced that Forxiga (dapagliflozin) has been accepted for restricted use within NHS Scotland by the Scottish Medicines Consortium (SMC).
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
AstraZeneca today announced that Forxiga (dapagliflozin) has been accepted for restricted use within NHS Scotland by the Scottish Medicines Consortium (SMC).